Quantinno Capital Management LP Boosts Stake in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Quantinno Capital Management LP grew its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 429.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 107,189 shares of the company's stock after acquiring an additional 86,952 shares during the period. Quantinno Capital Management LP's holdings in Dr. Reddy's Laboratories were worth $1,693,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Robeco Institutional Asset Management B.V. raised its stake in shares of Dr. Reddy's Laboratories by 453.8% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock valued at $180,620,000 after purchasing an additional 9,373,412 shares during the period. Renaissance Technologies LLC grew its holdings in Dr. Reddy's Laboratories by 382.9% during the 4th quarter. Renaissance Technologies LLC now owns 9,418,428 shares of the company's stock valued at $148,717,000 after buying an additional 7,467,979 shares in the last quarter. Aikya Investment Management Ltd grew its holdings in Dr. Reddy's Laboratories by 416.1% during the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock valued at $88,590,000 after buying an additional 4,523,303 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Dr. Reddy's Laboratories by 405.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 5,361,013 shares of the company's stock valued at $84,643,000 after buying an additional 4,301,212 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of Dr. Reddy's Laboratories by 397.2% in the fourth quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock worth $77,311,000 after buying an additional 3,911,404 shares in the last quarter. 3.85% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th.

Dr. Reddy's Laboratories Price Performance

Shares of RDY stock traded up $0.37 on Tuesday, reaching $14.75. The company's stock had a trading volume of 326,188 shares, compared to its average volume of 1,485,923. The company has a market capitalization of $12.31 billion, a P/E ratio of 23.46 and a beta of 0.33. Dr. Reddy's Laboratories Limited has a 12-month low of $12.26 and a 12-month high of $16.89. The stock's 50 day simple moving average is $13.60 and its 200-day simple moving average is $14.00. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its earnings results on Friday, May 9th. The company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.02. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. The business had revenue of $996.17 million for the quarter, compared to analyst estimates of $83.70 billion. As a group, equities analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.